Arcus (RCUS) Q2 Revenue Jumps 310%

Arcus Biosciences (NYSE:RCUS), a clinical-stage biotech focused on cancer immunotherapies, reported its second-quarter 2025 earnings on August 6, 2025. GAAP revenue and earnings per share both surpassed Wall Street expectations by a wide margin, with reported GAAP revenue at $160 million versus consensus estimates of $33.2 million. This beat was almost entirely due to a non-recurring $143 million GAAP revenue recognition tied to Gilead returning rights to one of Arcus’s late-stage drug programs. Earnings per share (GAAP) were break-even ($0.00) compared to an expected GAAP loss of $1.13 per share. Overall, the quarter featured an unusually large headline GAAP beat, continuing progress in its clinical pipeline, and steady financial resources to fund its research priorities. Source: Analyst estimates for the quarter provided by FactSet. Arcus Biosciences aims to develop therapies that harness the immune system to fight cancer. Its research focuses on several new drug candidates that may improve outcomes for patients with cancers like kidney, pancreatic, lung, and gastric cancers. The company’s main business revolves around clinical trials on molecules that target different immune pathways, including anti-TIGIT antibodies, HIF-2α inhibitors, CD73 inhibitors, and A2a/A2b adenosine receptor antagonists.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool